Before we get too far along in the new year, we thought we’d share a few highlights from 2022 – an extraordinary year of growth and influence for our cGMP biologics development and manufacturing facility supporting our leading efforts toward fully continuous biomanufacturing.
Our advanced cGMP manufacturing facility for biologics, J.POD®, represents a paradigm shift in biomanufacturing. Our cutting-edge AI/ML protein design technologies combined with industry-leading intensified continuous bioprocessing can help de-risk and accelerate biotherapeutics development – from lead generation to BLA while offering cost-effective and truly flexible clinical and commercial supply solutions.”
Paradigm Shift in Biologics / Capital Markets Day
J.POD Redmond WA (US) played center stage as the venue for Evotec’s second Capital Markets Day on 2-November 2022. Biologics industry investors and thought leaders congregated at J.POD to learn how, together, we are creating a paradigm shift in biologics. Guests experienced this shift firsthand with a tour of our state-of-the-art facility, through presentations and conversations with members of Evotec’s Management Board and our deeply experienced team. Watch the recorded Capital Markets Day webcast to learn more.
Expanded Partnership with Alpine Immune Sciences for Commercial Process Development
We expanded a multi-year partnership with Alpine for the development of a commercial process with a view to support commercial manufacturing of ALPN-303. Read the press release to learn more.
Collaboration with the U.S. Department of Defense
The U.S. Department of Defense (DOD) awarded Just – Evotec Biologics, Inc. a contract valued up to $49.9 M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Plague, an infectious disease caused by the bacterium Yersinia pestis (Y. pestis), is one of the designated targets of interest under the DOD’s Accelerated Antibodies Program. Read the full press release to learn more.
A Visit with the White House Office of Science and Technology (OSTP)
It was an honor to host the OSTP, Senior Advisor Dr. Matt Hepburn at J.POD Redmond in September 2022. We are aligned in our mission to accelerate access to biotherapeutics domestically and globally through scientific and technological innovation. Our promise to the DOD, OSTP and patients – continuous innovation!
Construction of a 2nd J.POD Biomanufacturing Facility
In September we broke ground and initiated the construction of J.POD Toulouse, France (EU) at Evotec’s Campus Curie in Toulouse, France. J.POD (EU) – a clone of J.POD Redmond and the first one on European ground, will employ our flexible J.POD technology to deliver much-needed clinical and commercial manufacturing capacity for biologics. The plant is expected to be operational in H2 2024 and will create upwards of 150 new high-skill jobs.
*The construction of J.POD® (EU) benefits from French government funding as part of the Investments for the future Programme (programme d’investissements d’avenir in French) and is also supported economically by the Occitanie Region and Toulouse Métropole.
J.POD wins CPHI Pharma Award 2022
J.POD won the CPhI Pharma Award 2022 for excellence in “Manufacturing Technology and Equipment.” We believe J.POD represents a paradigm shift in biologics manufacturing and are honored to have received this recognition, as the CPhI Pharma Awards celebrate cross-industry innovators in the field of pharma and biopharma companies worldwide. Learn more about our future plans for J.POD in the interview with Randal Bass, EVP Process Design & Biotherapeutic Operations.
Just – Evotec Biologics’ advancement toward a fully continuous manufacturing process was shared with industry at leading technical conferences in the US and EU:
- USP/Biophorum Workshop: Continuous Manufacturing
- ECI: Integrated Continuous Manufacturing V
- NIIMBL National Meeting
- Recovery of Biological Products XIX (RXIX)
J.POD Manufacturing Site Tour
Take a vitrual walk through our manufacturing facility and experience the cleanroom pods.